HIV-1 Tat-induced platelet activation and release of CD154 contribute to HIV-1-associated autoimmune thrombocytopenia

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 3, 2011, Pages 562-573

  Wang, J ^a   Zhang, W ^a   Nardi, M A ^b   Li, Z ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoantibody; CCR3; CD154; HIV; Tat; Thrombocytopenia

Indexed keywords

BETA3 INTEGRIN; CD40 LIGAND; CHEMOKINE RECEPTOR CCR3; CYCLIC AMP; TRANSACTIVATOR PROTEIN;

ADENOVIRUS; ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; B LYMPHOCYTE; CALCIUM TRANSPORT; CELL CULTURE; ELECTRON MICROSCOPY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; MOUSE; NONHUMAN; PLATELET MICROPARTICLE; PRIORITY JOURNAL; SPLEEN CELL; THROMBOCYTE; THROMBOCYTE ACTIVATION;

ANIMALS; B-LYMPHOCYTES; BLOOD PLATELETS; CALCIUM SIGNALING; CD40 LIGAND; CELL LINE; CELL-DERIVED MICROPARTICLES; CYCLIC AMP; GENES, TAT; HIV INFECTIONS; HIV-1; HUMANS; INTEGRIN BETA3; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICROSCOPY, ELECTRON, TRANSMISSION; MODELS, BIOLOGICAL; PLATELET ACTIVATION; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, CCR3; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSFECTION;

EID: 79952065234     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.04168.x     Document Type: Article

References (49)

1. Bierling P, Bettaieb A, Oksenhendler E. Human immunodeficiency virus-related immune thrombocytopenia. Semin Thromb Hemost 1995; 21: 68-75.
2. Najean Y, Rain JD. The mechanism of thrombocytopenia in patients with HIV infection. J Lab Clin Med 1994; 123: 415-20.
3. Li Z, Nardi MA, Karpatkin S. Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia. Blood 2005; 106: 572-6.
4. Li Z, Nardi MA, Wu J, Pan R, Zhang W, Karpatkin S. Platelet fragmentation requires a specific structural conformation of human monoclonal antibody against beta3 integrin. J Biol Chem 2008; 283: 3224-30.
5. Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. Autoimmun Rev 2002; 1: 329-37.
6. Levy JA. HIV pathogenesis: knowledge gained after two decades of research. Adv Dent Res 2006; 19: 10-6.
7. Ahmad R, Iannello A, Samarani S, Morisset R, Toma E, Grosley M, Ahmad A. Contribution of platelet activation to plasma IL-18 concentrations in HIV-infected AIDS patients. AIDS 2006; 20: 1907-9.
8. Holme PA, Muller F, Solum NO, Brosstad F, Froland SS, Aukrust P. Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection. FASEB J 1998; 12: 79-89.
9. Meabed MH, Taha GM, Mohamed SO, El-Hadidy KS. Autoimmune thrombocytopenia: flow cytometric determination of platelet-associated CD154/CD40L and CD40 on peripheral blood T and B lymphocytes. Hematology 2007; 12: 301-7.
10. Solanilla A, Pasquet JM, Viallard JF, Contin C, Grosset C, Dechanet-Merville J, Dupouy M, Landry M, Belloc F, Nurden P, Blanco P, Moreau JF, Pellegrin JL, Nurden AT, Ripoche J. Platelet-associated CD154 in immune thrombocytopenic purpura. Blood 2005; 105: 215-8.
11. Elzey BD, Sprague DL, Ratliff TL. The emerging role of platelets in adaptive immunity. Cell Immunol 2005; 238: 1-9.
12. Elzey BD, Tian J, Jensen RJ, Swanson AK, Lees JR, Lentz SR, Stein CS, Nieswandt B, Wang Y, Davidson BL, Ratliff TL. Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity 2003; 19: 9-19.
13. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001; 58: 4-43.
14. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 2002; 106: 896-9.
15. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 98: 1047-54.
16. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
17. Sprague DL, Sowa JM, Elzey BD, Ratliff TL. The role of platelet CD154 in the modulation in adaptive immunity. Immunol Res 2007; 39: 185-93.
18. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007; 100: 27-40.
19. Elzey BD, Grant JF, Sinn HW, Nieswandt B, Waldschmidt TJ, Ratliff TL. Cooperation between platelet-derived CD154 and CD4+ T cells for enhanced germinal center formation. J Leukoc Biol 2005; 78: 80-4.
20. Perez-Melgosa M, Hollenbaugh D, Wilson CB. Cutting edge: CD40 ligand is a limiting factor in the humoral response to T cell-dependent antigens. J Immunol 1999; 163: 1123-7.
21. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 2004; 22: 307-28.
22. Toubi E, Shoenfeld Y. The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity 2004; 37: 457-64.
23. Kuwana M, Nomura S, Fujimura K, Nagasawa T, Muto Y, Kurata Y, Tanaka S, Ikeda Y. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood 2004; 103: 1229-36.
24. Kornbluth RS. The emerging role of CD40 ligand in HIV infection. J Leukoc Biol 2000; 68: 373-82.
25. Kuwana M, Kawakami Y, Ikeda Y. Suppression of autoreactive T-cell response to glycoprotein IIb/IIIa by blockade of CD40/CD154 interaction: implications for treatment of immune thrombocytopenic purpura. Blood 2003; 101: 621-3.
26. Pugliese A, Vidotto V, Beltramo T, Petrini S, Torre D. A review of HIV-1 Tat protein biological effects. Cell Biochem Funct 2005; 23: 223-7.
27. Noonan D, Albini A. From the outside in: extracellular activities of HIV Tat. Adv Pharmacol 2000; 48: 229-50.
28. Urbinati C, Bugatti A, Giacca M, Schlaepfer D, Presta M, Rusnati M. alpha(v)beta3-integrin-dependent activation of focal adhesion kinase mediates NF-kappaB activation and motogenic activity by HIV-1 Tat in endothelial cells. J Cell Sci 2005; 118: 3949-58.
29. Urbinati C, Mitola S, Tanghetti E, Kumar C, Waltenberger J, Ribatti D, Presta M, Rusnati M. Integrin alphavbeta3 as a target for blocking HIV-1 Tat-induced endothelial cell activation in vitro and angiogenesis in vivo. Arterioscler Thromb Vasc Biol 2005; 25: 2315-20.
30. de Paulis A, De Palma R, Di Gioia L, Carfora M, Prevete N, Tosi G, Accolla RS, Marone G. Tat protein is an HIV-1-encoded beta-chemokine homolog that promotes migration and up-regulates CCR3 expression on human Fc epsilon RI+ cells. J Immunol 2000; 165: 7171-9.
31. Albini A, Ferrini S, Benelli R, Sforzini S, Giunciuglio D, Aluigi MG, Proudfoot AEI, Alouani S, Wells TNC, Mariani G, Rabin RL, Farber JM, Noonan DM. HIV-1 Tat protein mimicry of chemokines. Proc Natl Acad Sci USA 1998; 95: 13153-8.
32. Marone G, Florio G, Petraroli A, Triggiani M, de Paulis A. Human mast cells and basophils in HIV-1 infection. Trends Immunol 2001; 22: 229-32.
33. Gear AR, Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation 2003; 10: 335-50.
34. Clemetson KJ, Clemetson JM, Proudfoot AE, Power CA, Baggiolini M, Wells TN. Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. Blood 2000; 96: 4046-54.
35. Li Z, Nardi MA, Li YS, Zhang W, Pan R, Dang S, Yee H, Quartermain D, Jonas S, Karpatkin S. C-terminal ADAMTS-18 fragment induces oxidative platelet fragmentation, dissolves platelet aggregates and protects against carotid artery occlusion and cerebral stroke. Blood 2009; 113: 6046-7.
36. Hawley RG, Lieu FH, Fong AZ, Hawley TS. Versatile retroviral vectors for potential use in gene therapy. Gene Ther 1994; 1: 136-8.
37. Soneoka Y, Cannon PM, Ramsdale EE, Griffiths JC, Romano G, Kingsman SM, Kingsman AJ. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 1995; 23: 628-33.
38. White JG. Electron microscopy methods for studying platelet structure and function. Methods Mol Biol 2004; 272: 47-63.
39. Cerutti A, Zan H, Schaffer A, Bergsagel L, Harindranath N, Max EE, Casali P. CD40 ligand and appropriate cytokines induce switching to IgG, IgA, and IgE and coordinated germinal center and plasmacytoid phenotypic differentiation in a human monoclonal IgM+ IgD+ B cell line. J Immunol 1998; 160: 2145-57.
40. Xiao H, Neuveut C, Tiffany HL, Benkirane M, Rich EA, Murphy PM, Jeang KT. Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc Natl Acad Sci USA 2000; 97: 11466-71.
41. Tan KT, Tayebjee MH, Lynd C, Blann AD, Lip GY. Platelet microparticles and soluble P selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers. Ann Med 2005; 37: 61-6.
42. Sprague DL, Elzey BD, Crist SA, Waldschmidt TJ, Jensen RJ, Ratliff TL. Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles. Blood 2008; 111: 5028-36.
43. Fackler OT, Baur AS. Live and let die: Nef functions beyond HIV replication. Immunity 2002; 16: 493-7.
44. Swingler S, Brichacek B, Jacque JM, Ulich C, Zhou J, Stevenson M. HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection. Nature 2003; 424: 213-9.
45. Martin G, Roy J, Barat C, Ouellet M, Gilbert C, Tremblay MJ. Human immunodeficiency virus type 1-associated CD40 ligand transactivates B lymphocytes and promotes infection of CD4+ T cells. J Virol 2007; 81: 5872-81.
46. Re MC, Furlini G, Vignoli M, Ramazzotti E, Zauli G, La PM. Antibody against human immunodeficiency virus type 1 (HIV-1) Tat protein may have influenced the progression of AIDS in HIV-1-infected hemophiliac patients. Clin Diagn Lab Immunol 1996; 3: 230-2.
47. Re MC, Vignoli M, Furlini G, Gibellini D, Colangeli V, Vitone F, La Placa M. Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients. J Clin Virol 2001; 21: 81-9.
48. Phillips AN, Neaton J, Lundgren JD. The Role of HIV in serious diseases other than AIDS. AIDS 2008; 22: 2409-18.
49. Satchell CS, Cotter AG, O'Connor EF, Peace AJ, Tedesco AF, Clare A, Lambert JS, Sheehan GJ, Kenny D, Mallon PW. Platelet function and HIV: a case-control study. AIDS 2010; 24: 649-57.